Equity Research, Broker Reports, and media content on BASILEA PHARMACEUTICA-REG

  • Access the latest forecasts, broker valuations, multiples, and video content from the city about BASILEA PHARMACEUTICA-REG
  • See live updates from analysts, company announcements, and other news in a personalised/single dashboard

Research, Charts & Company Announcements

Research Tree provides access to ongoing research coverage, media content and regulatory news on BASILEA PHARMACEUTICA-REG. We currently have 5 research reports from 1 professional analysts.

Open
87.4
Volume
0.1m
Range
86.8/89.0
Market Cap
1,051,774,054m
52 Week
61.2/95.4
Date Source Announcement
27Apr17 17:32 GNW Basilea shareholders approve all resolutions proposed by the Board of Directors at the Ordinary General Meeting of Shareholders
21Apr17 06:15 GNW Basilea announces agreement with FDA on Special Protocol Assessments for antibiotic ceftobiprole phase 3 clinical studies in bloodstream and skin infections
06Apr17 06:15 GNW Data presented at AACR meeting indicate diverse tumor-targeting properties of Basilea's BAL101553 and show a combination potential with bevacizumab
27Feb17 06:15 GNW Basilea proposes Dr. Nicole Onetto as new member of the Board of Directors
20Feb17 06:15 GNW Basilea reports solid 2016 results and expects to double product sales in 2017
29Dec16 06:15 GNW Basilea names new member of its Extended Management Committee
02Dec16 06:15 GNW Basilea expands oncology drug candidate BAL101553 clinical phase 1/2a oral study to include glioblastoma patients
  • Frequency of research reports

     

  • Research reports on

    BASILEA PHARMACEUTICA-REG

  • Providers covering

    BASILEA PHARMACEUTICA-REG